Clinical trials: Ophthalmopathy
Glaucoma, Ocular Hypertension
Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
The main purpose is to compare the ocular hypotensive efficacy and safety of two concentrations of T4090 (Kinezodianone R HCl 0.2% and 0.3%) ophthalmic solution with Rhopressa® ophthalmic solution
- Trial name
- NCT06394973
- Testing
- T4090 0.2%, T4090 0.3%, Rhopressa®
- Where
- 24 sites in United States
- Volunteers
- 161 people
- Sponsor
- Laboratoires Thea
Cancer
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00096083
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Delcath Systems Inc.
Chronic Venous Disease, Chronic Venous Insufficiency, CVI
The ReCAna for Lower ExtremIty Venous OBstructions and In-StEnt Restenosis Registry
The goal of this observational study is to gather additional safety and performance (effectiveness) data on the device for the treatment of symptomatic lower extremity venous obstructions and occlusions.
- Conditions
- Chronic Venous Disease, Chronic Venous Insufficiency, CVI, Venous Thrombosis, Thrombosis (Stent Thrombosis)
- Trial name
- CALIBER (NCT07529756)
- Testing
- Recanalization and debulking
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Intervene, Inc.
Dry Eye Disease
Clinical Trial to Evaluate the Chronic Efficacy of OC-01 Nasal Spray on Signs of Dry Eye Disease (The MYSTIC Study)
The objective of this study is to evaluate the chronic safety and effectiveness of OC-01 Nasal Spray as compared to placebo on signs of dry eye disease (DED).
- Trial name
- NCT03873246
- Testing
- OC-01 0.1% 0.6 mg/ml, OC-01 (varenicline) nasal spray: 0.2 % (1.2 mg/ml)
- Where
- Mexico
- Volunteers
- 123 people
- Sponsor
- Oyster Point Pharma, Inc.
Pre-Eclampsia, Hypertension
Collection of Whole Blood Samples for the Evaluation of Preeclampsia (Pre-E) Biomarkers From Pregnant Women
Whole blood sample procurement study from pregnant women with signs and symptoms of Preeclampsia.
- Conditions
- Pre-Eclampsia, Hypertension, Proteinuria in Pregnancy, Thrombocytopenia
- Trial name
- NCT03767803
- Testing
- Non-interventional study
- Where
- 24 sites in United States
- Volunteers
- 344 people
- Sponsor
- Progenity, Inc.
Non-24-Hour Sleep-Wake Disorder
Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder
The purpose of this study is to evaluate the maintenance effect and safety of 20 mg tasimelteon versus placebo in subjects suffering from Non-24-Hour Sleep-Wake Disorder.
- Trial name
- NCT01430754
- Testing
- tasimelteon
- Where
- 22 sites in United States
- Volunteers
- 20 people
- Sponsor
- Vanda Pharmaceuticals
Keratoconus, Corneal Ectasia
Corneal Crosslinking for Treatment of Progressive Keratoconus or Corneal Ectasia
This randomized study compares 2 variations of corneal crosslinking for treatment of keratoconus or corneal ectasia.
- Trial name
- NCT07841470
- Testing
- Riboflavin 0.1% ophthalmic solution and pulsed light, Riboflavin 0.1% ophthalmic solution and non-pulsed light
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Price Vision Group
Glaucoma, Open-Angle, Ocular Hypertension
A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)
The purpose of this study is to evaluate the safety and IOP-lowering efficacy of Travoprost (0.004%) compared to Latanoprost (0.005%) in patients with chronic open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00051142
- Testing
- Travoprost, Latanoprost
- Where
- United States
- Sponsor
- Alcon Research
Dry Eye
Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease
Investigate the Safety and Efficacy of Two Concentrations of DE-110 Compared to Placebo for the Treatment of Dry Eye Disease
- Trial name
- NCT01239069
- Testing
- DE-110 ophthalmic suspension high dose, DE-110 ophthalmic suspension low dose
- Where
- 14 sites in United States
- Volunteers
- 140 people
- Sponsor
- Santen Inc.
Primary Open Angle Glaucoma, Ocular Hypertension
Study of LL-BMT1 in Patients With Elevated Intraocular Pressure
This is an open-label, Phase 2a clinical study of LL-BMT1 in patients with primary open-angle glaucoma and ocular hypertension. Study subjects will be treated for 7 days with a single dose of LL-BMT1.
- Trial name
- NCT04747808
- Testing
- LL-BMT1
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- MediPrint Ophthalmics, Inc.
Refractive Errors, Myopia
Clinical Performance Assessment of Two Silicone Hydrogel Daily Disposable Contact Lenses
The purpose of this study is to assess the overall clinical performance of a contact lens made with a modified manufacturing process.
- Trial name
- NCT05725317
- Testing
- LID220365 contact lens, LID006961 contact lens
- Where
- 7 sites in United States
- Volunteers
- 114 people
- Sponsor
- Alcon Research
Allergic Conjunctivitis
A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC)…
- Trial name
- NCT01881113
- Testing
- AC-170 0.24%, AC-170 0%
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Aciex Therapeutics, Inc.
Glaucoma
Glaucoma HFA / OCT Specificity Study
Study consists of five visits over a one to three month time period.
- Trial name
- NCT02708082
- Testing
- OCT scanning and HFA perimetry
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Carl Zeiss Meditec, Inc.
Cataracts
Cataract Surgery in Indian Patients With or Without LenSx® Laser
The purpose of this study is to record and analyze the profile and outcome of cataract patients receiving phacoemulsification (phaco) and artificial intraocular lens (IOL) implantation with or without femtosecond laser-assisted…
- Trial name
- NCT02605408
- Testing
- LenSx® laser system, Phacoemulsification
- Sponsor
- Alcon Research
Cataract
A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery
A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery
- Trial name
- NCT05550350
- Testing
- Dexycu
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Age-related Macular Degeneration
RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration
This is an open label, non-controlled, dose-escalating study assessing the safety, tolerability, and bioactivity of a single intravitreal (i.vt.) injection of RBM-007 in approximately nine subjects with exudative age-related…
- Trial name
- SUSHI (NCT03633084)
- Testing
- RBM-007 Injectable Solution
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Ribomic USA Inc
Vernal Keratoconjunctivitis
Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis
The objective of this study is to compare the efficacy of two different dosing regimen of NOVA22007 (1mg/ml ciclosporin/cyclosporine) eye drops, emulsion versus placebo (vehicle of the formulation) administered four times a day…
- Trial name
- NCT01751126
- Testing
- NOVA22007 ''Ciclosporin''
- Where
- 46 sites in United States, Croatia and 9 more
- Volunteers
- 169 people
- Sponsor
- Santen SAS
Retinitis Pigmentosa
Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene
The goal of this phase 1 clinical trial is to learn about the safety and efficacy of a gene therapy, VG901, in patients with a rare disorder of the eye called Retinitis Pigmentosa.
- Trial name
- NCT06291935
- Testing
- VG901
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- VeonGen Therapeutics GmbH
Diffuse Diabetic Macular Edema
Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema
The goal of the study is to evaluate the safety and tolerability of 4 different doses of iCo-007 Intravitreal Injection in patients with diffuse diabetic macular edema.
- Trial name
- NCT00886808
- Testing
- iCo-007 Intravitreal Injection
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- iCo Therapeutics Inc.
Neuromyelitis Optica Spectrum Disorders
A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders
This study is a phase I clinical study of the safety, tolerability, and pharmacokinetics of BAT4406F injection in patients with neuromyelitis optica spectrum disorders.
- Trial name
- NCT04146285
- Testing
- BAT4406F
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Bio-Thera Solutions
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.